Work

Cutaneous Dysesthesia Associated with Glucagon-Like Peptide-1 Receptor Agonists: Clinical Presentation, Dose Dependence, And Proposed Mechanisms

Year: 2026
Type: article
Abstract: Preeclampsia remains a formidable and heterogenous multisystemic obstetric syndrome, accounting for a substantial proportion of severe maternal morbidity and iatrogenic preterm birth worldwide. Despite decades of intense investigation, the clinical translation of predictive tools into effective preventive strategies continues to be hampered by the intricate pathophysiological heterogeneity of the disorder and the modest performance of traditional clinical risk factor-based screening. The advent of high-throughput omics technologies and a more granular understanding of the angiogenic-antiangiogenic imbalance, placental senescence, and syncytiotrophoblast-derived extracellular vesicle signaling have catalyzed the identification of an expanding array of candidate biomarkers, particularly those detectable within the first trimester maternal circulation. These putative indices, ranging from the well-established placental growth factor and pregnancy-associated plasma protein-A to novel candidates such as cell-free mitochondrial DNA, circulating non-coding RNAs, and specific inflammatory interleukins, offer a nuanced window into the subclinical placental dysfunction that precedes the clinical manifestation of hypertension and proteinuria by several weeks or even months. Concurrently, low-dose acetylsalicylic acid administered prophylactically, predominantly initiated prior to 16 weeks of gestation, has demonstrated a consistent, albeit variable, efficacy in mitigating the incidence of early-onset and preterm preeclampsia. However, a critical appraisal of the contemporary literature reveals a pervasive disconnect between the sophistication of our predictive algorithms and the precision of our prophylactic intervention. The observed phenomenon of aspirin resistance, alongside the recognition that a significant subset of high-risk parturients fail to demonstrate the anticipated antiplatelet effect or derive clinical benefit, underscores the urgent necessity for a more personalized therapeutic approach. This narrative review aims to synthesize the most recent evidence regarding the evolving landscape of preeclampsia biomarker discovery, with a particular emphasis on those modalities amenable to first-trimester screening and their potential to refine patient selection for acetylsalicylic acid prophylaxis. Furthermore, we critically examine the mechanistic interplay between these biomarkers and the pharmacodynamics of aspirin, exploring the hypothesis that specific biomarker profiles may not only predict the onset of disease but also delineate the likelihood of therapeutic responsiveness. By interrogating the bidirectional relationship between predictive indices and prophylactic efficacy, this work seeks to delineate a conceptual framework for a biomarker-guided, precision-medicine paradigm in preeclampsia prevention, moving beyond the current monolithic approach to aspirin administration toward a stratified, risk-adapted, and mechanistically informed antepartum care model.
Language: English
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7236270932
FWCI:
Cites: 14
Cited by:
Related to: 10